Background: Immunosuppression by biologic response modifiers (BRM) is a crucial component for successful organ transplantation. In addition to their variable effectiveness in the prevention of organ rejection, these medications have safety concerns that complicate therapeutic outcomes in organ transplant patients.
INTRODUCTION
E nd-stage organ failure is a common problem with limited treatment approaches beyond organ transplantation [1] . Number of candidates on waiting lists for transplantation continues to rise, while num-ber of donors continues to level off. In the United States, there were 11,663 organ donors and 23,360 organ transplants from January to October 2012 [2] . As of January 2013, there were 116,944 candidates on waiting lists with 74,451 (63.6%) being classified as active waitlisted who were eligible for organ offer at a given point of time [2] . In 2007, approximately 2.5 million individuals with end-stage organ failure died [3] ; nevertheless, pre-transplantation mortality rates were reduced among patients on waiting lists across all solid organs [4] . From 2010 to 2011, the number of patients on the waiting list for organ transplantation in the United States increased by 0.2% from 54,505 to 54,599; but the number of organ transplantations declined by 0.7% from 17,726 to 17,604 [4] . Organ transplantation improved patient's quality of life and overall survival; however, organ rejection by the host's immune system is a major complication of organ transplantation [1, 4] . Among adult transplant patients, the approximate incidence rates of acute rejection within the first year of transplantation are 40% for intestine, 19% for heart, 18% for lung, 15%-20% for pancreas, 15% for liver, and 10% for kidney [4] .
Immunosuppressive therapy aims to provide minimum suppression to the immune system to prevent transplant rejection while avoiding or minimizing complications of immunodeficiency. Generally, immunosuppressive medications are classified into corticosteroids (e.g., prednisolone) and biologic response modifiers (BRM) (e.g., cyclosporine). The introduction of BRM as an alternative to corticosteroids with its associated metabolic adverse reactions, is considered a breakthrough in prophylaxis against transplant rejection. However, these agents are associated with a myriad of safety concerns and not free from serious adverse outcomes that could complicate transplantation [5] . Some adverse reactions are well recognized for these agents; nonetheless, serious events are not well documented. By utilizing real-world data, this study aims to identify and characterize significant safety signals of serious adverse events reported for BRM used for the prophylaxis against transplant rejection.
MATERIALS AND METHODS
Unduplicated adverse event reports spontaneously submitted to the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) (formerly AERS) from October 1, 1997 to March 31, 2012 were used to apply a pharmacovigilance disproportionality analysis for the detection and characterization of serious adverse events associated with biologic response modifiers indicated for the prophylaxis against organ rejection. The FAERS is a database of spontaneously submitted adverse event reports for pharmaceutical products that is updated on a quarterly basis by FDA. Reports are submitted from health care professionals, consumers or caregivers, manufacturers, and other sources from the United States and other countries [6] . The FAERS is considered the primary source for the FDA to manage and monitor new adverse events reported for marketed pharmaceutical products [7] .
Identification of biologics response modifiers
The World Health Organization's Anatomical Therapeutic Chemical (ATC, January 2012) classification system was used to identify BRM. Table 1 lists individual agents approved for marketing in the United States. Adverse event reports that included BRM as primary suspects in the occurrence of the adverse event, and those with an indication for the prophylaxis against transplant rejection were included in the analysis. Figure 1 shows the applied database restriction criteria.
Identification of serious adverse events
The Preferred Term (PT) hierarchy of the Medical Dictionary for Regulatory Activities (MedDRA 15.0, March 2012) was used to identify serious adverse events that resulted in death, life-threatening experience, persistent or significant disability or incapacity, congenital anomaly or birth defect, initial or prolonged existing inpatient hospitalization, requirement for intervention, or any other important medical outcomes [8] . Within these reports, safety signals were evaluated for specific adverse events, and event PTs with significant safety signals were discussed in this Serious Adverse Events Reported for BRM Serious Adverse Events Reported for BRM report. Within FAERS, adverse events, seriousness outcome, and clinical indication for the reported drug were recorded using the PT hierarchy of MedDRA [6] .
Pharmacovigilance disproportionality analysis
Empirica Signal (7.3.341, November 2011, Oracle USA, Inc., Redwood City, CA, USA) was used to generate empirical Bayesian geometric mean (EBGM) and its corresponding 95% confidence intervals (EB05-EB95). An EBGM >1 was interpreted as "the reported adverse event for the corresponding drug was higher than that expected compared to other drugs and events in the database." Safety signals were identified if the lower limit of the 95% confidence interval (EB05) was >1, and drug-event combinations with EBGM ≥2 were considered significant safety signals [9, 10] . Signals with both EBGM and EB05 values ≥2 were considered significant safety signals that warrant regulatory action [6] .
RESULTS

Overview of serious adverse events reported for BRM
During the study period, a total of 12,151 adverse event reports was submitted for BRM and were classified as serious events. More than half of these serious events were attributed to sirolimus (n=6,749); about 19% were for mycophenolic acid (n=2,317); and about 9%, 7%, and 6% of serious event reports were respectively, for cyclosporine (n=1,067), tacrolimus (n=841), and antithymocyte immunoglobulin (n=725). The rest of BRM collectively contributed to 4% of the reports (n=452) ( Table 2 ). 2). Although mycophenolic acid and sirolimus showed safety signals of serious adverse events, none of these signals were significant. All the identified signals of "disease progression" for cyclophosphamide and "cytomegalovirus infection" for daclizumab were significant. Furthermore, significant signals that necessitate regulatory follow-up were only identified for cyclosporine in association with "neurotoxicity" and "graft versus host disease" adverse events (both EBGM and EB05 values exceeded 2). Table 4 shows the characteristics of BRM adverse event reports in which significant signals were identified. Approximately 34% of these events contributed to patient death (n=67); 6.5% were life-threatening (n=13); 32.1% led to hospitalization or required interventions (n=64); and 27.6% contributed to other serious outcomes (n=55). None of the events resulted in disabilities or congenital anomalies. About 46% of death reports were attributed to cyclosporine (n=31), 15% to antithymocyte immunoglobulin (n=10), 13.4% to cyclophosphamide (n=9), 12% to tacrolimus (n=8), 9% to azathioprine (n=6), and 4.4% to daclizumab (n=3). The vast majority of the reported lifethreatening events were for antithymocyte immunoglobulin (n=12); only one report was for tacrolimus. About 42% of the reported hospitalizations or intervention requirements were attributed to antithymocyte immunoglobulin (n=27), 29.6% to daclizumab (n=19), 17.1% to tacrolimus (n=11), 7.8% to cyclosporine (n=5), and 3.1% to azathioprine (n=2).
The median age for patients exposed to antithymocyte and experienced serious events that generated significant safety signals was 47.5 years; it was 64 years for azathioprine users, 37 for cyclosporine users, 48 for daclizumab users, and 54 years for tacrolimus users. About 54% of patients in antithymocyte immunoglobulin reports were males (n=37), 40% were females (n=27), and 6% with unknown sex (n=4). About 78% of reported azathioprine users were males (n=14), 17% were females (n=3), and one patient with unknown sex. Approximately 45% of the reported cyclosporine users were males (n=26), 7% were females (n=4), and 48% with unknown sex (n=28). Among reports for daclizumab, about 73% of patients were males (n=16), 18% were females (n=4), and 9% with unknown sex (n=2). Half of the patients in tacrolimus reports were males (n=12), 37.5% were females (n=9), and 12.5% had unknown sex reported (n=3). Patient de- The median number of medications concurrently administered with the respective BRM was three for reports of antithymocyte immunoglobulin, two for azathioprine and cyclophosphamide, one for cyclosporine, nine for daclizumab, and six for tacrolimus. Over 17% of antithymocyte immunoglobulin serious reports with significant signals did not have concomitantly used medications (n=12), corresponding to almost 57% of "anaphylactic reaction," 40% of "infusion related reaction," and 13% of each of "pulmonary edema" and "hypotension," events. About 8% of tacrolimus reports did not have additional medications reported (n=2), corresponding to 10% of "coma," and 7.1% of "tremor" events. Characteristics of individual adverse events for corresponding BRM are described in Table 4 .
DISCUSSION
The United States FAERS database was used to conduct a retrospective pharmacovigilance analysis of serious adverse events reported for BRM immunosuppressive medications that are indicated for the prophylaxis against transplant rejection. The majority of identified significant safety signals contributed to patient death; however, these signals should not be interpreted as causal links between exposure to BRM and occurrence of serious adverse events. The identified adverse events were consistent with the known safety profile of individual BRM; however, the seriousness of these events, e.g., death, is not established in the literature. For instance, proliferative disorders, e.g., T-cell lymphoma [11] , and opportunistic infections, e.g., cytomegalovirus infection, are common complications of immunosuppression [12] . Also, transplant recipients (16) 4 (25) 2 (13) (15) 2 (13) 6 (40) Anaphylactic reaction (7) 2 (29) 3 (43) (14) 1 (7) 1 (7) 9 ( are twice more likely to develop cancers than their counterparts without transplantation, and the risk increases greatly by infections with oncogenic viruses, e.g., Epstein-Barr virus, Kaposi sarcoma herpes virus, and human papillomavirus [13] ; this might be related to the duration and intensity of immunosuppression regardless of specific BRM [14] , and therefore, the association of cyclosporine with thyroid cancer should be interpreted with caution. Although daclizumab was associated with significant signal of cytomegalovirus infection, clinical trials showed fewer incidences among daclizumab users compared to placebo users [15] . In general calcineurin inhibitors, e.g., cyclosporine and tacrolimus, are associated with rare neurological and psychiatric adverse events, although coma and delirium have been reported for tacrolimus given at high doses [16] . Serums sickness and infusion-related reactions have been reported with antithymocyte immunoglobulin [17, 18] , but the occurrence of anaphylactic reactions is not well documented.
Data repositories of spontaneously submitted adverse events, e.g., FAERS are one of the key tools of routine assessment and management of risks associated with marketed pharmaceutical products. In addition to other limitations of spontaneously submitted adverse event data, these data are increasingly incomplete (e.g., missing patient demographic information for cyclophosphamide), variable reporting rates overtime, underreporting, duplicate reports, unverified source of submitted data, inability to adjust for important confounders, and missing information about temporality [6] . Since data mining algorithms, e.g., EBGM, are hypothesis generating techniques, they should not be used in isolation to clinical judgment and available epidemiological or clinical evidence. Furthermore, the estimated EBGM values should not be interpreted as incidence rates; rather they should be treated as the respective adverse event for the offending drug has been reported more than that expected compared to other adverse events and other drugs in the database during the specified reporting period. As an example of potential confounding effect by co-medications, systemic corticosteroids were mentioned in most of the reports with concurrent medications, and some reports included more than one class of BRM as secondary suspect in the occurrence of the adverse event.
In conclusion, utilization of BRM for the prophylaxis against transplant rejection is associated with serious adverse events that could be fatal and life-threatening. Transplant specialists should exercise caution when prescribing these medications to transplant patients and should monitor patient progress in terms of safety, tolerability and transplant outcomes throughout exposure period. Pharmacoepidemiological studies are required to evaluate the identified safety signals to help understand the benefit-risk profile of these medications.
